anandamide and Melanoma

anandamide has been researched along with Melanoma* in 2 studies

Other Studies

2 other study(ies) available for anandamide and Melanoma

ArticleYear
Anticancer activity of anandamide in human cutaneous melanoma cells.
    European journal of pharmacology, 2013, Oct-15, Volume: 718, Issue:1-3

    Cannabinoids are implicated in the control of cell proliferation, but little is known about the role of the endocannabinoid system in human malignant melanoma. This study was aimed at characterizing the in vitro antitumor activity of anandamide (AEA) in A375 melanoma cells. The mRNA expression of genes that code for proteins involved in the metabolism and in the mechanism of AEA action was assessed by RT-PCR. Cell viability was tested using WST-1 assay and the apoptotic cell death was determined by measuring caspase 3/7 activities. A375 cells express high levels of fatty acid amide hydrolase (FAAH), cyclooxygenase (COX)-2, cannabinoid receptor 1 (CB1), transient receptor potential cation channel subfamily V member 1 (TRPV1) and G-protein-coupled receptor 55 (GPR55) genes. AEA induced a concentration-dependent cytotoxicity with an IC50 of 5.8 ± 0.7 µM and such an effect was associated to a caspase-dependent apoptotic pathway. AEA cytotoxicity was potentiated by FAAH inhibition (2-fold increase, p<0.05) and mitigated by COX-2 or lipoxygenase (LOX) inhibition (5- and 3-fold decrease, respectively; p<0.01). Blocking CB1 receptors partially decreased AEA cytotoxicity, whereas selective antagonism on the TRPV1 barely affected the mechanism of AEA action. Finally, methyl-β-cyclodextrin, a membrane cholesterol depletory, completely reversed the cytotoxicity induced by the selective GPR55 agonist, O-1602, and AEA. Overall, these findings demonstrate that AEA induces cytotoxicity against human melanoma cells in the micromolar range of concentrations through a complex mechanism, which involves COX-2 and LOX-derived product synthesis and CB1 activation. Lipid raft modulation, probably linked to GPR55 activation, might also have a role.

    Topics: Antineoplastic Agents; Apoptosis; Arachidonic Acids; Cell Line, Tumor; Endocannabinoids; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Polyunsaturated Alkamides; Receptors, Cannabinoid; Skin Neoplasms; TRPV Cation Channels

2013
Revisiting CB1 receptor as drug target in human melanoma.
    Pathology oncology research : POR, 2012, Volume: 18, Issue:4

    Previous studies have indicated the antitumoral effect of human melanocytes, human melanoma cell lines expressing CB1 receptor (CB1), and of the peritumoral administration of endocannabinoids. In the present study, we systematically screened several human melanoma cell lines for the expression of CNR1 and demonstrated transcription of the authentic gene. The product of CNR1, the CB1 protein, was found localized to the cell membrane as well as to the cytoskeleton. Further, the studied human melanoma cell lines expressed functional CB1 since physiological and synthetic ligands, anandamide (AEA), Met-F-AEA, ACEA and AM251 showed a wide range of biological effects in vitro, for example anti-proliferative, proapoptotic and anti-migratory. More importantly, our studies revealed that systemic administration of a stable CB1 agonist, ACEA, into SCID mice specifically inhibited liver colonization of human melanoma cells. Since therapeutic options for melanoma patients are still very limited, the endocannabinoid-CB1 receptor system may offer a novel target.

    Topics: Animals; Apoptosis; Arachidonic Acids; Base Sequence; Cannabinoids; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Delivery Systems; Endocannabinoids; Humans; Ligands; Liver Neoplasms; Melanoma; Mice; Mice, SCID; Microscopy, Fluorescence; Molecular Sequence Data; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Receptor, Cannabinoid, CB1; Xenograft Model Antitumor Assays

2012